Essex Bio-Technology Limited (HKG:1061)
Hong Kong
· Delayed Price · Currency is HKD 3.950
+0.080 (2.07%)
At close: Mar 10, 2026
Essex Bio-Technology Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 1,718 | 1,670 | 1,737 | 1,318 | 1,638 | 978.11 | Upgrade
|
| Revenue Growth (YoY) | 3.10% | -3.87% | 31.82% | -19.54% | 67.43% | -23.55% | Upgrade
|
| Cost of Revenue | 179.34 | 171.15 | 174.94 | 128.38 | 241.89 | 184.28 | Upgrade
|
| Gross Profit | 1,538 | 1,499 | 1,562 | 1,189 | 1,396 | 793.83 | Upgrade
|
| Selling, General & Admin | 1,166 | 1,148 | 1,229 | 914.19 | 989.71 | 588.24 | Upgrade
|
| Other Operating Expenses | -16.18 | -4.26 | -18.51 | -26.83 | 12.24 | -46.01 | Upgrade
|
| Operating Expenses | 1,150 | 1,144 | 1,210 | 887.36 | 1,002 | 542.23 | Upgrade
|
| Operating Income | 388.32 | 354.79 | 351.57 | 301.97 | 393.82 | 251.6 | Upgrade
|
| Interest Expense | -5.45 | -6.09 | -11.21 | -11.47 | -9.22 | -1.42 | Upgrade
|
| Interest & Investment Income | 10.02 | 11.45 | 12.34 | 8.88 | 9.86 | 7.58 | Upgrade
|
| Earnings From Equity Investments | -1.12 | -2.91 | -1.64 | -0.19 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 391.77 | 357.24 | 351.06 | 299.18 | 394.46 | 257.76 | Upgrade
|
| Impairment of Goodwill | - | - | - | -25.83 | - | - | Upgrade
|
| Asset Writedown | 0 | -2.88 | -5.05 | -13.01 | - | -11.81 | Upgrade
|
| Legal Settlements | -10.08 | 21.14 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 4.91 | Upgrade
|
| Pretax Income | 381.69 | 375.5 | 346.01 | 260.34 | 394.46 | 250.85 | Upgrade
|
| Income Tax Expense | 68.51 | 68.28 | 70.75 | 34.93 | 48.49 | 31.93 | Upgrade
|
| Net Income | 313.18 | 307.22 | 275.26 | 225.41 | 345.97 | 218.93 | Upgrade
|
| Net Income to Common | 313.18 | 307.22 | 275.26 | 225.41 | 345.97 | 218.93 | Upgrade
|
| Net Income Growth | 19.13% | 11.61% | 22.11% | -34.85% | 58.03% | -27.63% | Upgrade
|
| Shares Outstanding (Basic) | 567 | 567 | 570 | 574 | 577 | 578 | Upgrade
|
| Shares Outstanding (Diluted) | 569 | 582 | 596 | 599 | 602 | 603 | Upgrade
|
| Shares Change (YoY) | -4.11% | -2.24% | -0.62% | -0.43% | -0.21% | -0.12% | Upgrade
|
| EPS (Basic) | 0.55 | 0.54 | 0.48 | 0.39 | 0.60 | 0.38 | Upgrade
|
| EPS (Diluted) | 0.55 | 0.53 | 0.47 | 0.38 | 0.58 | 0.37 | Upgrade
|
| EPS Growth | 22.45% | 13.38% | 22.52% | -34.14% | 55.93% | -27.09% | Upgrade
|
| Free Cash Flow | 253.46 | 324.07 | 318.17 | 293.29 | 319.12 | 202.14 | Upgrade
|
| Free Cash Flow Per Share | 0.45 | 0.56 | 0.53 | 0.49 | 0.53 | 0.34 | Upgrade
|
| Dividend Per Share | 0.130 | 0.120 | 0.090 | 0.065 | 0.095 | 0.050 | Upgrade
|
| Dividend Growth | 23.81% | 33.33% | 38.46% | -31.58% | 90.00% | -41.18% | Upgrade
|
| Gross Margin | 89.56% | 89.75% | 89.93% | 90.26% | 85.23% | 81.16% | Upgrade
|
| Operating Margin | 22.61% | 21.25% | 20.24% | 22.92% | 24.05% | 25.72% | Upgrade
|
| Profit Margin | 18.23% | 18.40% | 15.85% | 17.11% | 21.13% | 22.38% | Upgrade
|
| Free Cash Flow Margin | 14.75% | 19.41% | 18.32% | 22.26% | 19.49% | 20.67% | Upgrade
|
| EBITDA | 433.27 | 400.71 | 402.67 | 336.24 | 419.02 | 274.03 | Upgrade
|
| EBITDA Margin | 25.22% | 24.00% | 23.18% | 25.52% | 25.59% | 28.02% | Upgrade
|
| D&A For EBITDA | 44.95 | 45.92 | 51.09 | 34.27 | 25.2 | 22.44 | Upgrade
|
| EBIT | 388.32 | 354.79 | 351.57 | 301.97 | 393.82 | 251.6 | Upgrade
|
| EBIT Margin | 22.61% | 21.25% | 20.24% | 22.92% | 24.05% | 25.72% | Upgrade
|
| Effective Tax Rate | 17.95% | 18.18% | 20.45% | 13.42% | 12.29% | 12.73% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.